Serum biomarkers for predicting Crohn's disease activity: The role of bilirubin, uric acid, and the C-reactive protein/albumin ratio.

Abstract

Crohn's disease is a chronic, progressive inflammatory condition of the gastrointestinal tract that requires long-term assessment of disease activity. There is a growing need for convenient serum biomarkers to reduce the need for invasive endoscopic evaluations. Our study aims to explore the predictive value of serum biomarkers, specifically total bilirubin, uric acid, and the C-reactive protein/albumin ratio, for disease activity in Crohn's disease. We conducted a retrospective study at the Second Hospital of Anhui Medical University (China), consisting of 170 patients with Crohn's disease and 100 healthy controls. Clinical characteristics and laboratory biomarkers were collected and analyzed. Among the patients, 77 active Crohn's disease patients who had complete follow-up data were included in a longitudinal analysis to assess biomarker dynamics. Compared to healthy controls, Crohn's disease patients exhibited lower bilirubin and albumin levels, but higher C-reactive protein and C-reactive protein/albumin ratio, trends that intensified with disease progression. Following therapy, albumin, C-reactive protein and C-reactive protein/albumin ratio changed significantly in both remission and active groups, whereas a significant increase in total bilirubin was exclusive to the remission group. Receiver operating characteristic analysis indicated that C-reactive protein/albumin ratio had the highest discriminatory power for disease activity (area under the curve [AUC]= 0.903), outperforming C-reactive protein alone (AUC = 0.894), albumin (AUC = 0.719) and total bilirubin (AUC = 0.648). Regarding uric acid, no significant associations were identified overall, apart from a single weak correlation in Spearman's analysis. Our findings support a potential serological remission hypothesis for Crohn's disease, characterized by a post-treatment rise in total bilirubin, together with a decrease in C-reactive protein to approximately 5.3 mg/L and the C-reactive protein/albumin ratio to about 0.136. This hypothesis warrants prospective validation.